arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

download Export Data

Beta Bionics, Inc.

BBNX

$15.89 ▲ +1.75 (+12.38%) at close

4 Visible periods

24 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Poor

Bearish

auto_awesome

Analytical Summary

Beta Bionics, Inc. faces fundamental challenges with weakness in Return on Common Equity (%) and Profit Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $644.0M

Dividend Yield —

Revenue Growth 53.9% ↘

Op. Margin -71.5% ↘

ROIC -19.7% ↘

FCF / Share $-1.39 ↗

Trailing P/E —

Price / Book 2.5x

FCF Yield —

Debt / Equity —

info Valuation on last close. End-of-day price, Aug 7, 2026.

4-Year Financial Trajectory

Annual

Metric Value Trend Year over Year Percentile

Revenue Total top-line sales

$100.25M

↑ +53.9% —

Net Income Profit after all expenses

$-73.20M

↓ -33.7% —

Operating Margin Operating profit as % of sales

-71.5%

↓ -2.9% 3th

FCF / Share Free cash flow per share

$-1.39

↑ +82.9% —

trending_up

Bullish Indicators

No bullish signals detected.

warning

Bearish Risks

Operating Margin (%)Operating Margin (%) is in the bottom quartile
Profit Margin (%)Profit Margin (%) is in the bottom quartile
Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability ↑

Returns

Cash Quality →

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 4 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗
Revenue Growth YoY (%)	53.9% Excellent Excellent Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+574%)	442.9% Excellent Excellent Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+5437%)	—	—
EPS Growth YoY (%)	79.0% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	-3.5% Weak Weak Year-over-year change in earnings per share Optimal: > 10%	—	—
Net Income Growth YoY (%)	-33.7% Weak Weak Year-over-year change in net income	-24.2% Weak Weak Year-over-year change in net income	—	—
FCF Growth YoY (%)	82.9% Excellent Excellent Year-over-year change in free cash flow	-31.1% Weak Weak Year-over-year change in free cash flow	—	—

💰 Are margins durable? 4 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗
Operating Margin (%) (%)	-71.5% Weak ↑ Weak Improving Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-577%)	-69.5% Weak Weak Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-563%)	-298.9% Weak Weak Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-2092%)	—
Profit Margin (%) (%)	-73.0% Weak ↑ Weak Improving Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-708%)	-84.1% Weak Weak Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-801%)	-367.6% Weak Weak Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-3164%)	—
FCF Margin (%) (%)	-56.1% Weak ↑ Weak Improving Free cash flow as a percentage of revenue Optimal: > 10%	-79.3% Weak Weak Free cash flow as a percentage of revenue Optimal: > 10%	-273.8% Weak Weak Free cash flow as a percentage of revenue Optimal: > 10%	—
FCF / Net Income (x)	0.77x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	0.94x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	0.74x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	—

🎯 Is capital allocation efficient? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗
Return on Invested Capital (%)	-19.7% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	14.6% Good Good Return earned on debt + equity capital invested Optimal: > 10%	13.9% Good Good Return earned on debt + equity capital invested Optimal: > 10%	—
Return on Capital (%) (%)	-21.8% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-30.2% Weak Weak Operating profit relative to total assets Optimal: > 10%	-32.6% Weak Weak Operating profit relative to total assets Optimal: > 10%	—
Return on Common Equity (%) (%)	-25.5% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-270%)	22.3% Excellent Excellent Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+49%)	21.7% Excellent Excellent Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+45%)	—

⚖️ Is the balance sheet risky? 1 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗
Net Debt (USD)	$-31.58M	$-30.43M	$-26.57M	—

📊 What does each share earn? 6 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗
Revenue per Share (USD)	$2.47	$10.23	$2.26	—
Basic EPS, GAAP (USD)	$-1.81	$-8.60	$-8.31	—
Free Cash Flow per Share (USD)	$-1.39	$-8.12	$-6.19	—
Book Value per Share (USD)	$6.48	$-36.80	$-38.30	—
Tangible Book Value per Share (USD)	$6.48	$-36.80	$-38.30	—
Basic Weighted Avg Shares (shares)	40.53M	6.37M	5.30M	—

🏦 How resilient is the balance sheet? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗
Working Capital (USD)	$236.98M	$111.78M	$93.02M	—
Total Equity (USD)	$287.61M	$-245.36M	$-203.10M	$-170.03M

📋 What is driving earnings? 4 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗
Sales/Revenue/Turnover (USD)	$100.25M	$65.12M	$11.99M	—
Depreciation Expense (USD)	$1.57M	$1.15M	$1.23M	—
Net Income, GAAP (USD)	$-73.20M	$-54.76M	$-44.10M	—
Operating Cash Flow (USD)	$-50.92M	$-48.27M	$-32.45M	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 4 years · 12 quarters

Beta Bionics, Inc.

Analytical Summary

4-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Statement lens

Benchmark Lens

Signals

Percentile Rankings

Peer Comparison

Compare BBNX with peers